{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Figure 1:', 'Study KCP-330-023 Overview', '*Patients progressing on Vd', 'may cross over to SVdX', 'treatment if they are able to', 'tolerate continued', 'ortezomib-Dexamethasone (Vd*) (n=182)', 'bortezomib or to SdX if they', 'have significant tolerability', '(~30%', '(~22', 'issues with bortezomib,', '(~33 months)', 'PFS', 'months)', 'following IRC-confirmed PD.', 'events)', 'lelinexor-Bortezomib-Dexamethasone (SVd) (n=182)', '1st', '2nd', 'PFS Primary', 'PFS IA', 'PFS IA', 'Analysis', '1st IA after ~30% PFS events for possible sample size re-estimation', '2nd IA after ~75% PFS events for futility or superiority', 'PFS primary analysis (~33 months after first patient is randomized)', 'Abbreviations: IA = interim analysis; IRC = Independent Review Committee; ITT = intent-to-treat; PD = progressive disease; PFS = progression-free survival; SdX = selinexor', 'plus low-dose dexamethasone treatment after crossover; SVd = selinexor plus bortezomib plus low-dose dexamethasone; SVdX = SVd treatment after crossover; Vd = bortezomib', 'plus low-dose dexamethasone.', 'Confidential', 'Page 34', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '4.', 'INTRODUCTION', '4.1.', 'Multiple Myeloma', '4.1.1.', 'Disease Background', 'Multiple myeloma (MM) is the second most common hematological malignancy (after', \"non-Hodgkin's lymphoma [NHL]), representing 1% of all cancers and 2% of all cancer deaths.\", 'With over 30,000 new cases and approximately 12,700 deaths from MM anticipated in 2018 in', 'the United States of America (USA) (ACS 2018) and about twice as many in Europe, there is an', 'unmet medical need for therapies in patients with relapsed or refractory multiple myeloma', '(RRMM) that has progressed on available agents.', '4.1.2.', 'MM Treatment', 'The treatment of MM has improved over the last 20 years and overall survival (OS) has', 'increased considerably with the approval of non-chemotherapeutic agents including', 'immunomodulatory drugs, such as thalidomide, lenalidomide, and pomalidomide, and the', 'proteasome inhibitors (PIs) bortezomib, carfilzomib, and oral ixazomib (which was approved', 'more recently). These agents have served as \"backbone\" therapies for patients with MM, are', 'often used in combination (eg, lenalidomide with bortezomib), and are typically combined with', '\"low-dose\" dexamethasone (ie, <40 mg/week). Additional drug classes, including histone', 'deacetylase inhibitors such as panabinostat, along with anti-CD38 (daratumumab) and anti-CS1', '(elotuzumab) monoclonal antibodies (mAbs), have recently been approved and are all', 'contributing to prolonged survival in MM. Despite this progress, essentially all patients will', 'develop refractory MM and succumb to the disease.', 'The prognosis remains poor for patients with RRMM who have already received at least 1 prior', 'anti-MM regimen. For these patients, the median progression-free survival (PFS) is 6.2 to', '9.4 months with bortezomib (Richardson 2007, Dimopoulos 2016) and median OS is', 'approximately 29.8 months (Richardson 2007).', 'Second-line combination therapies have a significant burden of toxicity with extended sequelae,', 'representing significant unmet medical need. Peripheral neuropathy, in particular, has an', 'extended long-term burden for patients.', '4.2.', 'Selinexor', 'A summary of the relevant background information for selinexor, including the mechanism of', 'action, nonclinical and clinical studies, and potential risks is presented below. Please refer to the', \"Selinexor Investigator's Brochure (IB) for more detailed information.\", '4.2.1.', 'Selinexor Mechanism of Action', 'Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export', '(SINE) compound that specifically blocks exportin 1 (XPO1). Selinexor binds covalently to', 'cysteine 528 in the cargo binding pocket of XPO1 and shuts down its nuclear export activity', '(Neggers 2016, Neggers 2015, Hing 2016). This results in marked nuclear accumulation of TSPs', 'Confidential', 'Page 35', 'Version 4.0']\n\n###\n\n", "completion": "END"}